Non-invasive sensor measures blood haemoglobin by optical analysis of
finger
25 June 2006 Nes Ziona, Israel. A non-invasive haemoglobin/hematocrit
monitoring system developed by OrSense Ltd has been shown to accurately
measure levels of haemoglobin/hematocrit in both hospital and ambulatory
settings.
The study was conducted by Prof. Alain Berrebi from the Institute of
Hematology, Kaplan Medical Center, Rehovot, Israel and presented at the 11th
Congress of the European Hematology Association (EHA), June 15-18, 2006 in
Amsterdam. “Non-invasive haemoglobin/hematocrit measurements have many
potential advantages including the prevention of pain and potential
transmission of infectious diseases and the reduced need for trained
technicians,” said Prof. Berrebi from the Institute of Hematology, Kaplan
Medical Center, Rehovot, Israel and the principal investigator of the study.
“Based on the study’s conclusions, we believe that OrSense’s non-invasive
haemoglobin/hematocrit monitoring system could be used for accurate, safe
and easy to operate anaemia monitoring and early haemorrhage identification
in hospitals, physicians’ offices and blood donation centres,” said Prof.
Berrebi. The NBM-100 uses a ring-shaped cuff applied to the patient’s
finger. The device is based on “occlusion spectroscopy”, OrSense’s
proprietary measurement technology. This generates optical signals across
the finger which overcome the key technological barrier related to the very
low signal to noise ratio and non-specificity, inherent in competing
approaches. Analysis of the signal provides the sensitivity necessary to
measure haemoglobin/hematocrit concentrations, blood glucose levels and SpO2
levels. Clinical trials of the OrSense device, the NBM-100, were conducted
in a blood donation centre, an oncology clinic and a haematology clinic. The
studies were carried out on a group of 304 adult subjects, 155 females and
149 males. The results provided by the NBM-100 were compared to measurements
obtained by conventional invasive methods. The mean haemoglobin/hematocrit
level measured was the same for the invasive, venous measurements and the
non-invasive NBM-100 measurements. The mean relative absolute error was 7.9%
and the correlation between the two devices was r=0.9. The bias between the
two methods was a negligible 0.4%.
Lior D. Ma’ayan, Chief Executive Office, OrSense said, "Non-invasive
measurements are key for early detection and monitoring of life threatening
diseases. We believe that monitoring of patients in hospitals and at home
will be transformed by the ability to deliver accurate and continuous
non-invasive monitoring of critical blood parameters.” To
top |